Saturday 17 October 2026
Export OSRH’s income statement to Excel — free account
OSR Health, Inc.
OSRH Healthcare Biotechnology
OSR Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 million, down 17.7% from fiscal 2024. In the quarter to June 2026, revenue fell 72.2%, EPS fell 200.0%, free cash flow fell 398.8% and total debt rose 28.2%, each against the same quarter a year earlier.
0.22
0.02
+10.00%
Follow OSRH
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
3.34 | 3.76 | 7.12 | 5.82 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(4.24) | (10.21) | (18.69) | (4.35) | |
P/B ratio |
0.09 | 0.09 | 0.15 | 0.08 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
4.04 | 4.76 | 8.40 | 7.99 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(4.04) | (3.19) | (4.19) | (2.01) | |
EV/FCF |
(4.04) | (2.90) | (3.87) | (1.89) | |
Quick Ratio |
0.18 | 0.12 | 0.11 | 0.11 | |
Current Ratio |
0.21 | 0.16 | 0.16 | 0.18 | |
Net Debt/EBITDA |
(1.52) | (0.65) | (2.69) | (5.86) | |
Debt/Assets |
2.44% | 2.54% | 2.85% | 3.26% | |
Debt/Equity |
0.03 | 0.03 | 0.04 | 0.04 | |
Asset Turnover |
0.03 | 0.02 | 0.02 | 0.01 | |
Operating CF/Net income |
1.27 | 0.08 | 0.34 | 2.85 | |
Capex/Depreciation |
(0.04) | (0.22) | 0.00 | 0.00 | |
Interest Coverage |
(86.64) | (15.61) | (117.54) | (238.81) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
647.63% | 1,708.68% | 790.64% | 988.12% | |
Intangible Assets out of Total Assets |
0.98 | 0.98 | 0.98 | 0.98 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(3.48) | (3.79) | (2.24) | (3.69) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(619.69%) | (228.57%) | (55.00%) | (115.63%) | |
Free Cash Flow Yield |
(29.94%) | (43.56%) | (30.43%) | (72.55%) | |
Revenue per Share |
0.03 | 0.02 | 0.02 | 0.01 | |
Operating CF per Share |
(0.13) | (0.05) | (0.03) | (0.07) | |
Capex per Share |
0.00 | (0.03) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.13) | (0.08) | (0.03) | (0.07) | |
Cash per Share |
0.10 | 0.09 | 0.05 | 0.05 | |
Shareholders Equity per Share |
6.31 | 6.51 | 4.08 | 3.80 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.31 | 6.51 | 4.08 | 3.80 | |
Free Cash Flow |
(2.81) | (1.58) | (1.00) | (2.42) | |
Working Capital |
(11.83) | (14.35) | (14.97) | (12.87) | |
Capital Expenditures |
(0.09) | (0.51) | — | — | |
Net Current Asset Value |
(39.93) | (41.38) | (41.87) | (38.85) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.15 | 1.34 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | 0.66 | 0.56 | 0.50 | |
Average Payables |
4.46 | 4.45 | 7.78 | 7.78 | |
Average Inventory |
— | 0.56 | 0.60 | 0.40 | |
Average Assets |
98.96 | 173.24 | 173.37 | 176.02 | |
Average Common Equity |
64.20 | 135.12 | 129.84 | 132.03 |
Columns are period end dates